ImmuCell
ICCC
30 hedge funds and large institutions have $5.47M invested in ImmuCell in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 4 closing their positions.
3% more capital invested
Capital invested by funds: $5.32M → $5.47M (+$151K)
0.3% less ownership
Funds ownership: 13.65% → 13.35% (-0.3%)
3% less funds holding
Funds holding: 31 → 30 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$65.5K |
| 2 |
MWM
Mission Wealth Management
Santa Barbara,
California
|
+$50.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$38K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$19.3K |
| 5 |
HL
HeadInvest LLC
Portland,
Maine
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFMC
Empire Financial Management Company
New York
|
-$210K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$33.8K |
| 3 |
HPC
HM Payson & Co
Portland,
Maine
|
-$31.1K |
| 4 |
EFS
Essex Financial Services
Essex,
Connecticut
|
-$15.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14K |
ICCC Hedge Fund Activity: Q3 2023 in Review
30 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q3 2023, worth a combined $5.47M — up 2.8% from $5.32M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ICCC and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $65.5K. The largest seller was Empire Financial Management Company, exiting entirely with an estimated $210K sold.
- 30 institutional investors held ImmuCell (ICCC) as of Q3 2023, down from 31 in Q2 2023.
- Funds reported $5.47M of ImmuCell stock for Q3 2023, up 2.8% quarter-over-quarter.
- 3 funds opened new ImmuCell positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest ImmuCell buyer in Q3 2023 was Morgan Stanley, an estimated $65.5K added.
- The largest ImmuCell seller in Q3 2023 was Empire Financial Management Company, an estimated $210K sold.
Based on aggregated 13F filings for Q3 2023.